C4 Therapeutics, Inc.
About C4 Therapeutics, Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $35.9M
- Net income
- -$105.0M
- Total assets
- $359.1M
- Market cap
- $425.7M
- Operating margin
- -320.5%
- Net margin
- -292.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $35.9M
- Operating expenses
- $151.2M
- Operating income
- -$115.2M
- Income tax
- $121.0K
- Net income
- -$105.0M
- EPS (basic)
- $-1.27
- EPS (diluted)
- $-1.27
Balance sheet
- Total assets
- $359.1M
- Current assets
- $258.1M
- Total liabilities
- $102.5M
- Current liabilities
- $33.0M
- Shareholders’ equity
- $256.6M
Cash flow
- Operating cash flow
- -$98.7M
- Investing cash flow
- -$8.6M
- Financing cash flow
- $126.4M
- Net cash flow
- $19.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $425.7M
- EPS (diluted)
- $-1.27
- Shares outstanding
- 118.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 2, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $105.0M in FY2025.
- Revenue grew 8% from FY2020 to FY2025.
- Trading 18% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review C4 Therapeutics, Inc..
Write a review
News about C4 Therapeutics, Inc.
News & sentiment via Polygon.io
